Clinical Trial Update: Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating recombinant human interleukin-21 in combination with sunitinib for stage IV renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)
• recombinant human interleukin-21 (interleukin-21)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Cancer, Renal Cell Carcinoma | Phase 2 | Status: COMPLETED